Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficerafusp alfa + Pembrolizumab in 1L Recurrent/Metastatic HNSCC
NCT07807163Phase 2Recruiting
- Sponsor
- Bicara Therapeutics
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Bicara Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07807163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807163.